| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The MG-132 (negative control) is not a drug and thus has no specific biological target. Its purpose is to act as a true negative control, having no significant inhibitory effect on the proteasome or calpain, thereby allowing researchers to attribute observed effects specifically to the active inhibitor, MG-132.
|
|---|---|
| ln Vitro |
By design, this compound is inactive. It should not inhibit the proteasome or calpain. Its activity is defined as the absence of activity, confirming that any observed biological effect in the active MG-132 treated group is due to target inhibition and not a general property of the peptide backbone.
|
| ln Vivo |
Not applicable. As a negative control, it is not expected to have any specific activity in vivo. It can be used alongside the active MG-132 to control for non-specific peptide effects, such as minor cytotoxicity or off-target effects, in animal models.
|
| Enzyme Assay |
Standard in vitro proteasome inhibition assays are used to validate the negative control. The 20S proteasome is incubated with a fluorogenic peptide substrate (e.g., Suc-LLVY-AMC) in the presence of either the active MG-132 or the negative control. The amount of free fluorescent AMC (7-amino-4-methylcoumarin) produced is measured over time. The active MG-132 will inhibit the reaction, while the negative control will not, confirming the lack of activity of the negative control.
|
| Cell Assay |
Standard cellular protocols involve treating cells (e.g., cancer cell lines or primary neurons) with a concentration of MG-132 that induces a specific phenotype (e.g., the accumulation of ubiquitinated proteins, ER stress, or apoptosis). Parallel cultures are treated with an equal concentration of the MG-132 (negative control). If the phenotype is only observed in the MG-132 treated group and not the control group, it suggests that the effect is due to proteasome inhibition rather than a non-specific peptide effect.
|
| Animal Protocol |
Not applicable. As a negative control, it is not used as a primary treatment in animal experiments. Instead, it can be used in conjunction with the active drug to prove target specificity. This is not a routine protocol. In most standard animal studies, a true negative control compound is considered less critical than a vehicle control because the potential for non-specific effects in vivo is typically low.
|
| ADME/Pharmacokinetics |
For in vitro applications, a working stock solution is prepared by dissolving the negative control in DMSO. The stock solution can be stored at -20degC. When treating cells, the compound is diluted into cell culture medium to the desired final concentration, with the final DMSO concentration typically kept below 0.1% to avoid cytotoxicity. Its solubility in DMSO is 100 mg/mL.
|
| Toxicity/Toxicokinetics |
As an inactive peptide, the negative control is not intended to be toxic. At high doses, it may cause some non-specific peptide toxicity, but it is expected to be significantly less toxic than the aldehyde-containing active MG-132. No specific toxicology data is provided.
|
| References |
[1]. Harhouri K, et al. MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation. EMBO Mol Med. 2017 Sep;9(9):1294-1313.
|
| Additional Infomation |
MG-132 (negative control) is a research-grade peptide used as a chemical control in cell biology and biochemistry. Its only purpose is to provide a negative reference for experiments using the active proteasome inhibitor, MG-132. It is not a drug and is not intended for any therapeutic or diagnostic use. This product is strictly for laboratory research use.
|
| Molecular Formula |
C26H41N3O5
|
|---|---|
| Related CAS # |
MG-132;133407-82-6;(R)-MG-132;1211877-36-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
